SPECIAL NOTICE
A -- Canine Freeze Dried Plasma- Sole Source Notice
- Notice Date
- 10/28/2019
- Notice Type
- Special Notice
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- Department of the Army, US Army Medical Research Acquisition Activity, U.S. Army Medical Research Acquisition Activity, Attn: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014, Maryland, 21702-5014, United States
- ZIP Code
- 21702-5014
- Solicitation Number
- W81XWH-FY20-CFDP-Sole-Source
- Archive Date
- 11/28/2019
- Point of Contact
- Peter D. Mitchell, Phone: 3016191355
- E-Mail Address
-
peter.d.mitchell8.civ@mail.mil
(peter.d.mitchell8.civ@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- NOTICE OF INTENT TO AWARD A SOLE SOURCE The United States Army Medical Research Acquisition Activity (USAMRAA) intends to issue a Cost Plus Fixed Fee sole source contract under the authority of FAR 6.302-1 (a) (2) - Only One Responsible Source and No Other Services will Satisfy Agency Requirements, on or about 31 January 2020 to BodeVet, Inc., 9210 Corporate Blvd, Suite 310 Rockville, MD 20850, on behalf of the United States Army Medical Materiel Development Activity (USAMMDA). The Government has a requirement for the purpose of conducting a Phase 2/3 clinical trial that supports a treatment indication for hemorrhagic shock secondary to trauma, and associated dosing, for canine lyophilized platelets and canine lyophilized plasma (in combination and separately) as U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) products. BodeVet is uniquely positioned to execute the necessary development activities and is the only entity capable of adding a hemorrhagic shock indication to their StablePlate RX TM and StablePlas TM products. BodeVet is the regulatory sponsor of these products and there are no other known manufacturer producing both lyophilized canine plasma and platelets. Interested contractors may identify their interest and bona fide capability to fulfill this requirement, to include both lyophilized canine plasma and platelets. This notice of intent is not a request for competitive proposals. Interested parties who believe they can meet this requirement shall submit information about their capabilities no later than 10:00 AM EST, 13 NOVEMBER 2019. All questions and responses concerning this notice shall be emailed to Peter D. Mitchell at peter.d.mitchell8.civ@mail.mil. All information shall be furnished at no cost or obligation to the Government. No solicitation will be made available. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. A determination by the Government not to compete this proposed solicitation based upon responses to this notice is solely within the discretion of the Government. Telephone inquiries will not be accepted.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/USA/USAMRAA/DAMD17/W81XWH-FY20-CFDP-Sole-Source/listing.html)
- Record
- SN05484102-W 20191030/191028230536-16668f3723b5848c2bfb3bfb5f4c0891 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |